Vimarsana
Biggest News Aggregation in the World

Conditionally Activated News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Conditionally Activated. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Conditionally Activated Today - Breaking & Trending Today

Switch Therapeutics Appoints Charles Allerson, Ph.D., as Chief Technology Officer - Vimarsana News

Switch Therapeutics Appoints Charles Allerson, Ph.D., as Chief Technology Officer

SOUTH SAN FRANCISCO, Calif., January 03, 2024--Switch Therapeutics today announced the appointment of Charles Allerson, Ph.D., as Chief Technology Officer (CTO).

Source: yahoo.com
Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS) - Vimarsana News

Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)

Presentation will highlight versatility of DARPin designs in enabling conditional activation of the immune system to fight tumors, addressing toxicities seen with other targeted modalities Review includes differentiated mechanisms of action including tumor-localized activation, avidity-driven selectivity and novel SWITCH-DARPin approach ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech com

Source: yahoo.com
Molecular Partners to Present on DARPin Oncology - Vimarsana News

Molecular Partners to Present on DARPin Oncology

Presentation will highlight versatility of DARPin designs in enabling conditional activation of the immune system to fight tumors, addressing toxicities...

Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody ... - Vimarsana News

Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody ...

Presentation will highlight versatility of DARPin designs in enabling conditional activation of the immune system to fight tumors, addressing toxicities seen with other targeted modalities

Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer?s 38th Annual Meeting - Vimarsana News

Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer?s 38th Annual Meeting

Werewolf Therapeutics, Inc. announced preliminary first-in-human clinical data from initial monotherapy dose-escalation cohorts in the Company?s lead clinical program, WTX-124x2101. This clinical...